February 17, 2022 -- Walking Fish Therapeutics has completed an oversubscribed series A financing round, raising a total of $73 million. The proceeds will accelerate platform development and further establish Walking Fish in the rapidly emerging B-cell therapeutics field, the firm said.
Since the launch of the series A financing round in September, Walking Fish's platform for protein factories and oncology applications has continued to demonstrate positive preclinical data across multiple indications, according to the company.
Walking Fish Therapeutics is seeking to advance a pipeline of B-cell therapeutics for oncology, rare disease, regenerative medicine, autoimmune disease, and recombinant antibody production.
The company's investment was co-led by Northpond Ventures and First Spark Ventures, with support from other investors.